Boston Scientific Stock - Analysts Reassess After Sharp Pullback

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 14:18 UTC. Details in the imprint.

Boston Scientific (US10117L1017) has seen its stock come under renewed pressure in recent days. Analysts are now reassessing their targets and risk assumptions after the latest pullback, according to several updated research notes.

What recent analyst notes show

In late May, Piper Sandler cut its price target on Boston Scientific shares to $65 from $90 but maintained a positive stance on the company’s long-term growth drivers, according to a summary of the call on a market data platform.

The reduction followed a period of relative underperformance and reflected a more cautious valuation framework rather than a fundamental downgrade of the business model, as the broker highlighted ongoing demand in cardiology and neuromodulation devices.

Consensus expectations and rating mix

Across Wall Street, consensus still skews positive, with a majority of analysts rating Boston Scientific stock at Buy or equivalent, while a smaller group stays at Hold, based on compiled broker data from major financial portals.

Average 12-month price targets remain above the current share price, implying upside from recent levels, even after downward revisions from some houses in response to the stock’s volatility and the broader medtech sector reset.

The product behind the stock

Boston Scientific generates most of its revenue from minimally invasive medical devices, including coronary stents and other cardiovascular products used to treat heart disease, as well as solutions in areas such as electrophysiology and urology.

Where the stock trades today

The shares of Boston Scientific (US10117L1017) trade on the New York Stock Exchange under the ticker BSX; the latest verified price data is available from the exchange and leading financial data providers in US dollars.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.